Top Circulating Tumor Cell Companies

The rise in the number of people with cancer around the world as well as the desire for a quick, accurate, and low-cost method of diagnosing cancer through liquid biopsies rather than traditional methods are the major reasons for the increasing popularity of the global circulating tumor cell market. With the ability to monitor and track tumor growth, metastases, and responses to therapy through a simple blood test, liquid biopsy is proving to be an excellent alternative to the more invasive and time-consuming option of taking samples of tissue directly from the patient's body.

Industry Overview

According to SkyQuest Technology “Circulating Tumor Cell Market By Technology (Circulating Tumor Cells CTC Detection & Enrichment Methods, CTC Direct Detection Methods), By Specimen, By Product, By End Use, By Region- Industry Forecast 2025-2032,” Global Circulating Tumor Cell Market is projected to grow at a CAGR of over 9.6% by 2032, on account of Clinical need for real-time, minimally invasive tumor monitoring and treatment response assessment. The development of new and innovative technologies, such as microfluidics, immunomagnetic isolation, and molecular characterization, will help increase the accuracy of tests performed using CTCs while providing more clinical opportunities due to improved sensitivity and utility. Various types of funding in cancer research, the expansion of the use of personalized medicine in the treatment of patients, and the incorporation of CTC technology into many of these treatments will help to further develop the use of CTCs in both the laboratory and the clinic.

Top 10 Global Circulating Tumor Cell Companies

1. QIAGEN N.V.

QIAGEN N.V. is a company that is a multinational supplier of technologies for assays and samples for molecular diagnostics. Founded in Germany in 1984, one area of Qiagen's strength in the market for circulating tumor cells (CTC) is its ability to provide the "Sample to Insight" approach which consists of kits, reagents, and instruments for the entire workflow, including blood sample preparation, and the ability to effectively enrich for CTCs..

2. F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. is a leader in pharmaceuticals and in-vitro diagnostics and is headquartered in Switzerland. Founded in 1896, Roche is a global leader in both pharmaceuticals and in-vitro diagnostics, and although a major supplier of isolation products for CTCs, Roche has a significant influence on the market through its status as a dominant player in in-vitro diagnostics and tissue-based diagnostics for cancer.

3. Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. has its corporate headquarters in the United States and was established in 1952. Bio-Rad is significant in the life sciences and clinical diagnostics market and has several products that are important to this market, including the Genesis Cell Isolation System with Celselect Slides, which employs gentle microfluidics and size-based capture technology for isolating cells and the Droplet Digital PCR technology, which is very sensitive.

4. Menarini Silicon Biosystems

Menarini Silicon Biosystems, based in Italy, began commercializing its unique CELLSEARCH® System in 2005. Menarini is currently the only company in the world with an FDA-cleared CTC enumeration test that helps assess prognoses for metastatic breast, prostate, and colorectal cancers.

5. Illumina, Inc. (U.S.)

Illumina was established in 1998 and has since remained the leader in Next-Generation Sequencing technology (NGS). NGS technology does not specifically capture CTCs, but NGS sequencing will be critical to perform downstream genomic profiling after CTC capture.

6. Bio-Techne Corporation (U.S.)

Bio-Techne was began in 1981 and provides extensive catalog of high-quality reagents, instruments, and precision diagnostics. In the CTC industry, its brands offer many of the essential reagents for conducting successful CTC research, including validated antibodies and proteins, as well as some of the most sophisticated instrumentation needed to analyze collected CTCs.

7. Miltenyi Biotec B.V. & Co. KG (Germany)

Founded in 1989, Miltenyi is a privately-held company known for developing the MACS® Technology (Magnetic-Activated Cell Sorting) that utilizes superparamagnetic microbeads linked to target-specific antibodies to magnetically isolate and enrich the number of rare cells, such as CTCs, very efficiently.

8. ANGLE plc (U.K.)

ANGLE is a specialist established in 1994 and developed a proprietary Parsortix® system, which is the first commercially available technology to capture intact cancer cells from blood to provide FDA approval specifically for the metastatic breast cancer indication.

9. Epic Sciences

Epic Sciences was established in the United States in 2008 and has developed an innovative approach to CTC analysis. With its unique, enrichment-free, image-based analysis platform, Epic uses high-resolution imaging and machine learning to detect and characterize rare CTCs by analyzing all nucleated cells in a blood sample on a single slide rather than isolating them from the blood.

10. RareCyte

RareCyte, Inc. is in the United States and was incorporated in 2010. RareCyte's integrated AccuCyte®-CyteFinder® platform offers the integrated solution for the unbiased and sensitive detection, enumeration, and visualization of CTCs with a complete workflow for CTCs. RareCyte's CytePicker® Retrieval Module is a feature that allows for the precise collection and physical separation of individual CTCs (or clusters) from the slide while preserving the integrity of the sample for subsequent deep genomic analysis.

Other Leading Global Circulating Tumor Cell Companies

• Thermo Fisher Scientific Inc.
• Sysmex Corporation
• Exact Sciences Corporation
• Biocept, Inc.
• Biolidics Limited (Developer of ClearCell® FX)
• STEMCELL Technologies
• Creatv MicroTech, Inc. (Developer of CellSieve™)
• Ikonisys Inc.
• NeoGenomics Laboratories (Acquired Inivata)
• ScreenCell

Conclusion

The circulating tumour cell market is predicted to see steady growth, as acceptable use of liquid biopsy technology becomes increasingly recognised as an increasingly valuable adjunct in precision oncology, and translational research. Technological developments continued clinical validation, and the growing emphasis on personalised/Precision Oncology methods have strengthened the position of CTCs in early detection, prognosis, and monitoring/treatment. Future development and growth of the market will largely depend upon improved standardisation/decreased costs through more elaborate and rigorous research efforts, improved, supportive regulation, and collaboration between diagnostic/product development companies and research institutions.